Hiv Clinical Trial
Official title:
Cultural Adaptation and Piloting of an Avatar Delivered Smoking Cessation Intervention for Low Income Smokers in Baltimore City Living With HIV
Verified date | November 2019 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
One population of tobacco users that is severely affected by the consequences of smoking is
people living with HIV (PLWH). Between 40-84% of PLWH smoke, a percentage that has remained
constant since the first studies of smoking in HIV were conducted in the 1990's. Overall,
smoking related morbidity and mortality is also greatly increased among PLWH smokers.
Compared with PLWH nonsmokers, PLWH who smoke have more than 5 times the risk of
non-HIV-related mortality and almost 4 times the risk of all-cause mortality. Compared with
the general population, incidence ratio of smoking related cancers (eg, lung, head, neck,
bladder and esophageal) is more than 5 times higher. At a critical time when advances in HIV
care are providing an opportunity for prolonged life, smoking is significantly impeding the
health of PLWH.
To produce meaningful changes in smoking, however, treatment will have to be acceptable and
engaging to this population as well as feasible and sustainable to implement in a busy
clinic. Novel technology-based interventions that incorporate evidence-based behavioral and
pharmacologic interventions for smoking and are culturally tailored offer real solutions to
these implementation barriers. Research shows that internet- or computer-delivered
interventions (CDI) that are tailored and interactive can be efficacious in reducing smoking
and are significantly more effective than usual care or written self-help materials. CDIs can
also be readily adapted to different sociodemographic characteristics of a patient population
because content is modular and menu driven. Moreover, technology-based interventions appear
as effective as counselor-delivered interventions in reducing smoking. This growing body of
evidence strongly suggests that these interventions offer promise in reducing smoking, the
potential to reach significantly more patients, and the ability to overcome barriers of cost,
implementation, and cultural nonspecificity. The goal of this pilot study is test to examine
feasibility, acceptability of a computer-delivered smoking cessation intervention for PLWH,
and to determine if intervention participation results in increased readiness to quit smoking
and increased confidence in ability to quit smoking.
Status | Completed |
Enrollment | 40 |
Est. completion date | September 1, 2018 |
Est. primary completion date | September 1, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Age >=18 - A patient in the Johns Hopkins University (JHU) Bartlett Clinic - Smoked >100 cigarettes in their lifetime - Current daily smoker (verified by exhaled carbon monoxide) - English speaking. Exclusion Criteria: - Individuals will be excluded if they do not meet the above requirements |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins University | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Readiness to change smoking behaviour | Self-report on the Alcohol and Other Drug Contemplation Ladder, 1-10 Visual Analog Scale with 0- no readiness and 10- full readiness | immediately post-intervention | |
Secondary | Engagement in Smoking Cessation Services | Self-Reported Use of Quitline or pharmacotherapy for smoking cessation which will based on a questionnaire. | 8 weeks post-intervention | |
Secondary | Confidence in ability to quit smoking | Self report on visual analog scale measuring confidence in ability to quit smoking on visual analog scale 1-100 with a higher value representing higher confidence | immediately post-intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |